业内人士普遍认为，从长期看，海外不确定性因素增加给医药板块投资带来不确定性。新华财经南京9月28日电（记者朱程） 今年上半年，国内BD（一种医药企业通过战略合作、许可交易、并购等商务拓展活动，整合资源、加速研发并拓展市场的行为）交易金额超2024年全年，折射出我国医药行业质态提升。受此带动下，多家医药上市公司半年报业绩出现改善，叠加多项重磅政策出台，令二级市场整体呈现回暖态势。近日，记者走访多家...
Source Link业内人士普遍认为，从长期看，海外不确定性因素增加给医药板块投资带来不确定性。新华财经南京9月28日电（记者朱程） 今年上半年，国内BD（一种医药企业通过战略合作、许可交易、并购等商务拓展活动，整合资源、加速研发并拓展市场的行为）交易金额超2024年全年，折射出我国医药行业质态提升。受此带动下，多家医药上市公司半年报业绩出现改善，叠加多项重磅政策出台，令二级市场整体呈现回暖态势。近日，记者走访多家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.